Retatrutide vs Tirzepatide: What's the Difference?

Retatrutide vs. Tirzepatide: Which Weight Loss Option is Right for You?

Retatrutide is generating headlines for its weight loss results. But if you’re already taking tirzepatide, does that mean a better option is around the corner? The short answer is that these medicines work differently. Retatrutide’s trial results are promising, but as of September 2026, tirzepatide is an FDA-approved treatment, while retatrutide remains investigational. We also don’t yet have results from a completed trial directly comparing the two.

Understanding the Mechanisms: Two Receptors vs. Three

Tirzepatide activates two hormone receptors: GIP and GLP-1. It is the active ingredient in Zepbound, which is approved for weight management in eligible adults, and Mounjaro, which is approved for type 2 diabetes. On the other hand, retatrutide activates those same two receptors plus glucagon. Researchers are studying whether that third action provides additional benefits. Both medications are administered as once-weekly injections in the relevant studies.

| Receptors Targeted | U.S. Status | Availability |

|------------------------|------------------|------------------|

| Tirzepatide | FDA-approved for specific uses | Available by prescription for approved uses |

| Retatrutide | Investigational; not FDA-approved | Available only through clinical trials |

What Do the Weight Loss Studies Show?

In the SURMOUNT-1 trial, adults taking the highest studied dose of tirzepatide experienced an average weight reduction of 20.9% at 72 weeks. In Lilly’s TRIUMPH-1 trial, adults taking 12 mg of retatrutide had an average weight reduction of 28.3% at 80 weeks, compared with just 2.2% in the placebo group. The retatrutide figure comes from company-reported Phase 3 results.

While those numbers are exciting, 20.9% versus 28.3% is not a direct comparison. The studies enrolled different participants, ran for different lengths of time, and utilized different trial designs. A registered study is currently comparing retatrutide with tirzepatide directly; its results will provide a clearer answer about their relative effects.

Results also vary by population. In another Phase 3 trial, participants with type 2 diabetes taking 12 mg of retatrutide lost an average of 20.8% at 80 weeks. This variability is one reason a single headline percentage cannot predict what any individual will experience.

What About Side Effects?

Digestive symptoms are common with both medications. In TRIUMPH-1, Lilly reported nausea, diarrhea, constipation, and vomiting as some of the most common adverse events associated with retatrutide. At the 12 mg dose, 11.3% of participants stopped treatment due to adverse events, compared with 4.9% in the placebo group. Its longer-term safety profile is still being evaluated.

Tirzepatide has an established prescribing label that covers common digestive side effects and warnings about potential issues, including pancreatitis, gallbladder disease, and dehydration-related kidney injury. Its label also carries a boxed warning about thyroid C-cell tumors seen in rats and advises against use by individuals with a personal or family history of medullary thyroid cancer or MEN2. A clinician can help review how these cautions apply to your health history.

Can You Get Retatrutide Now?

Retatrutide has not been approved for public use. Lilly states that it is available only to participants in its clinical trials. The FDA indicates that retatrutide cannot be used in compounding under federal law. Products advertised online as “retatrutide” may contain uncertain ingredients or quality; they are not a shortcut to the studied medication.

Lilly plans to submit retatrutide to the FDA in the first quarter of 2027. This submission would initiate a regulatory review, but it does not guarantee approval or an availability date.

What Matters If You’re Already Taking Tirzepatide?

Retatrutide’s results are a reason to follow the research, not a reason to abandon a treatment that is working for you. Weight change is only part of the picture. Factors such as tolerability, nutrition, strength, health conditions, and your personal goals matter too.

For adults over 40, it is especially useful to discuss how to maintain adequate protein intake and resistance training while losing weight. If you are considering starting, stopping, or changing medication, it’s important to review the decision with your prescribing clinician.

The takeaway: Tirzepatide is an available, FDA-approved option for eligible patients. Retatrutide is a promising three-receptor medicine still under study. A completed direct comparison, fuller safety data, and FDA review will tell us much more than competing weight loss headlines can today.

My Personal Experience with Retatrutide

I have been taking retatrutide and have been loving it. I started with tirzepatide, which worked amazingly, but I still didn't have much energy with it. Results vary with every individual, but personally, it has changed my life for the better. It reduces inflammation incredibly well for me, and I have reached my weight loss goal.

The GLP-1 receptor is not as strong as tirzepatide, so I found myself more hungry at first. I used this to my advantage by eating more protein and making mindful food choices throughout the day, which is why it worked better for me. It is still only a tool; you cannot maintain bad habits like drinking alcohol and eating sugar all day and expect any GLP-1 to work for you.

Sources that provide it do not offer it publicly, and they will name it differently. You have to ask for it by name as it is still not FDA approved. Others may buy it from research sites that are not intended for human or veterinary use. I recommend starting with a lower dose than you did with tirzepatide or semaglutide. Less is more with this one when first starting out due to the third component—glucagon—which turns fat into energy.

Healthy Aging Well provides education, not individualized medical advice. Medication decisions should be made with a qualified healthcare professional.